Clinical Trial Detail

NCT ID NCT04070768
Title Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Big Ten Cancer Research Consortium
Indications

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin + Venetoclax

Venetoclax

Age Groups: adult senior

No variant requirements are available.